Biological E on Thursday also announced a licensing agreement for further development of a safe, effective and affordable recombinant protein-based covid-19 vaccine candidate which is now being developed at US-based Baylor College of Medicine.
Mexican Foreign Minister Marcelo Ebrard said his government would announce the deal on Thursday, adding that President Andres Manuel Lopez Obrador and his Argentinian counterpart supported the deal.
Vaccine candidates of companies such as Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), and Johnson and Johnson (NYSE: JNJ) are either in late-stage human trials or nearing them.
They will initially produce 150 to 250 million doses of the vaccine to supply all of Latin America except Brazil, which had already entered into a separate agreement in June to produce the vaccine for their country. The third phase of the vaccine trial, which began July 27, is the first government-funded Phase 3 clinical trial for a COVID-19 vaccine in the nation, according to HHS.
"We'll be prioritizing the vulnerable populations", Varela said at the Mexican president's daily news conference, noting that the pricing, while still not final, was not expected to exceed $4 per dose. However, experts say if testing goes well, a vaccine could be available to the public in early 2021.
Mr Fernandez said that the deal puts Argentina in a position of ease since the country would be able to get the vaccine when accessible and at a reasonable price. In a meeting of the National Expert Group on Wednesday, it was made a decision to build digital infrastructure which could take care of all aspects related to the Covid-19 vaccine starting from its procurement and last mile delivery to different sections of the population.
Azar says the U.S.is combining the powers of its government, economy and biopharmaceutical industry to "deliver as quickly as we can for the benefit of the United States' citizens, but also for the people of the world, safe and effective vaccines".
The government has reached similar deals with several other pharmaceutical companies producing other vaccine candidates.